{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:46:24Z","timestamp":1784882784678,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Soonchunhyang University Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02739-z","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:48:32Z","timestamp":1761191312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Jae Sik","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Il","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bae Kwon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah Ram","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2739_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4143\/crt.2023.447","volume":"55","author":"MJ Kang","year":"2023","unstructured":"Kang MJ, Jung K-W, Bang SH, Choi SH, Park EH, Yun EH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat. 2023;55:385\u201399. https:\/\/doi.org\/10.4143\/crt.2023.447.","journal-title":"Cancer Res Treat"},{"key":"2739_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.adro.2019.01.004","volume":"4","author":"ND Scherzer","year":"2019","unstructured":"Scherzer ND, DiBiase ZS, Srivastav SK, Thomas R, DiBiase SJ. Regional differences in the treatment of localized prostate cancer: an analysis of surgery and radiation utilization in the United States. Adv Radiat Oncol. 2019;4:331\u20136. https:\/\/doi.org\/10.1016\/j.adro.2019.01.004.","journal-title":"Adv Radiat Oncol"},{"key":"2739_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104:778\u201389. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2739_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I. Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51:963\u201374. https:\/\/doi.org\/10.3109\/0284186X.2012.719635.","journal-title":"Acta Oncol (Madr)"},{"key":"2739_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391:1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med"},{"key":"2739_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13014-018-1182-z","volume":"13","author":"Y Park","year":"2018","unstructured":"Park Y, Park HJ, Jang W, Il, Jeong BK, Kim H-J, Chang AR. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15\u201301). Radiat Oncol. 2018;13:230. https:\/\/doi.org\/10.1186\/s13014-018-1182-z.","journal-title":"Radiat Oncol"},{"key":"2739_CR7","unstructured":"Schaeffer E, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. NCCN Guideline for Prostate Cancer (Version 1.2025). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed December 17, 2024)."},{"key":"2739_CR8","unstructured":"Hueting T. MSKCC nomogram: probability of lymph node involvement in prostate cancer patients (includes biopsy cores). Available from: https:\/\/www.evidencio.com\/models\/show\/440 (accessed December 4, 2024)."},{"key":"2739_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029.","journal-title":"Int J Radiat Oncol"},{"key":"2739_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2739_CR11","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2:e188006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006.","journal-title":"JAMA Netw Open"},{"key":"2739_CR12","doi-asserted-by":"publisher","first-page":"E291","DOI":"10.1016\/j.ijrobp.2019.06.1833","volume":"105","author":"YW Lin","year":"2019","unstructured":"Lin YW, Wang SC. Long-term outcomes of stereotactic body radiotherapy for localized prostate cancer: a 10-year experience at a single institution. Int J Radiat Oncol Biol Phys. 2019;105:E291. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.1833.","journal-title":"Int J Radiat Oncol"},{"key":"2739_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.09.009","author":"TAC Kennedy","year":"2024","unstructured":"Kennedy TAC, Ong WL, Quon H, Cheung P, Chu W, Chung H, et al. Stereotactic radiation therapy for localized prostate cancer: 10-year outcomes from three prospective trials. Int J Radiat Oncol Biol Phys. 2025;121:325\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.009.","journal-title":"Int J Radiat Oncol"},{"key":"2739_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/pros.24657","volume":"84","author":"GR D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino GR, Badalamenti M, Stefanini S, Baldaccini D, Franzese C, Faro LL, Lo, et al. Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low\u2010intermediate risk prostate cancer. Prostate. 2024;84:368\u201375. https:\/\/doi.org\/10.1002\/pros.24657.","journal-title":"Prostate"},{"key":"2739_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27:192\u2013201. https:\/\/doi.org\/10.1038\/s41391-023-00712-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2739_CR16","doi-asserted-by":"publisher","first-page":"101625","DOI":"10.1016\/j.adro.2024.101625","volume":"9","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qureshi MM, Batra S, Truong M-T, Mak KS. Consecutive daily versus every other day stereotactic body radiation therapy scheduling for stage I non-small cell lung cancer. Adv Radiat Oncol. 2024;9:101625. https:\/\/doi.org\/10.1016\/j.adro.2024.101625.","journal-title":"Adv Radiat Oncol"},{"key":"2739_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0167-8140(96)01770-7","volume":"40","author":"AL Zietman","year":"1996","unstructured":"Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996;40:159\u201362. https:\/\/doi.org\/10.1016\/0167-8140(96)01770-7.","journal-title":"Radiother Oncol"},{"key":"2739_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00005392-199608000-00033","volume":"156","author":"WR Lee","year":"1996","unstructured":"Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer. J Urol. 1996;156:450\u20133. https:\/\/doi.org\/10.1097\/00005392-199608000-00033.","journal-title":"J Urol"},{"key":"2739_CR19","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ijrobp.2008.12.067","volume":"75","author":"MJ Zelefsky","year":"2009","unstructured":"Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys. 2009;75:1350\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.12.067.","journal-title":"Int J Radiat Oncol"},{"key":"2739_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","volume":"6","author":"AU Kishan","year":"2016","unstructured":"Kishan AU, Wang P-C, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, et al. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol. 2016;6:268\u201375. https:\/\/doi.org\/10.1016\/j.prro.2015.11.002.","journal-title":"Pract Radiat Oncol"},{"key":"2739_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-717X-9-42","volume":"9","author":"M Anwar","year":"2014","unstructured":"Anwar M, Weinberg V, Chang AJ, Hsu I-C, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014;9:42. https:\/\/doi.org\/10.1186\/1748-717X-9-42.","journal-title":"Radiat Oncol"},{"key":"2739_CR22","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.radonc.2024.110642","volume":"202","author":"CS Dejonckheere","year":"2025","unstructured":"Dejonckheere CS, Caglayan L, Glasmacher AR, Wiegreffe S, Layer JP, Nour Y, et al. Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: a scoping review and meta-analysis. Radiother Oncol. 2025;202:110642. https:\/\/doi.org\/10.1016\/j.radonc.2024.110642.","journal-title":"Radiother Oncol"},{"key":"2739_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ijrobp.2019.06.2539","volume":"105","author":"NY Jiang","year":"2019","unstructured":"Jiang NY, Dang AT, Yuan Y, Chu F-I, Shabsovich D, King CR, et al. Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2019;105:628\u201336. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.2539.","journal-title":"Int J Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02739-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02739-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02739-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:48:35Z","timestamp":1761191315000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02739-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2739"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02739-z","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of all participant institutions and conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was not required as the study involved a retrospective review with minimal risk to the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}